Actively Recruiting
Sit Less, Interact and Move More (SLIMM) 2 Study
Led by Srinvasan Beddhu · Updated on 2025-06-05
156
Participants Needed
2
Research Sites
278 weeks
Total Duration
On this page
Sponsors
S
Srinvasan Beddhu
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.
CONDITIONS
Official Title
Sit Less, Interact and Move More (SLIMM) 2 Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to <60 mL/min/1.73m²
- Able to perform resistance training
- Access to compatible smartphone or device (Android, Kindle, Apple) or desktop/laptop with internet or mobile network
You will not qualify if you...
- Type 1 Diabetes
- History of gastroparesis or paralytic ileus
- Sedentary time 25 minutes per hour or less at baseline (measured by accelerometer)
- Contraindications to semaglutide such as pancreatitis history or family/personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
- Previous bariatric surgery
- Medical condition likely to limit survival to less than 1 year
- Anticipated dialysis or kidney transplant within 6 months
- Factors limiting adherence to interventions as judged by study team
- Pregnant or incarcerated individuals
- Enrolled in other interventional drug or device trials
- Unable to provide informed consent
- Hospitalization or major interventional procedures within past 60 days
- Known or suspected hypersensitivity to tegaderm
- Use of any GLP-1 receptor agonist within 30 days prior to screening
- Currently classified as New York Heart Association Class IV Heart Failure
- Daytime use of supplemental oxygen
- Presence of metastatic cancer
- Current use of mobility aids
- Living in the same household as another study participant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Stanford University
Stanford, California, United States, 94305
Actively Recruiting
2
University of Utah
Salt Lake City, Utah, United States, 84108
Actively Recruiting
Research Team
A
Amara Sarwal, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here